Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 2/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 3/20 | 0.31 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37383 | 0.81 | XDH (0.38) | XDHKMT2A | |
| SCHEMBL11456966 | 0.79 | XDH (0.37) | XDH | |
| Tetrabuthylammonium SCHEMBL3029323 | 0.77 | POLA1 (0.48) | POLA1XDHCDK1CCNB1CCNA2 | |
| SCHEMBL9882917 | 0.74 | HDAC1 (0.42) | XDHCDK1CCNB1KMT2A | |
| SCHEMBL9278627 | 0.74 | KMT2A (0.44) | POLA1XDHCDK1CCNB1KMT2A | |
| SCHEMBL12963516 | 0.69 | HTT (0.44) | XDHKMT2A | |
| SCHEMBL7110908 | 0.68 | XDH (0.41) | XDHCDK1 | |
| SCHEMBL4451632 | 0.68 | XDH (0.40) | XDH | |
| Purine SCHEMBL10869620 | 0.67 | RPS6KA5 (0.33) | — | |
| Hydrochloric Acid SCHEMBL6657448 | 0.66 | PDK2 (0.37) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101848891-A | Preparation of synthetic nucleosides by pi-allyl transition metal complex formation | UNIV EMORY | 2010-09-29 | — | — | CN | disclosed |
| US-20100204463-A1 | Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation | EMORY UNIVERSITY | 2010-08-12 | — | — | US | disclosed |
| EP-2185508-A1 | PREPARATION OF SYNTHETIC NUCLEOSIDES VIA pi-ALLYL TRANSITION METAL COMPLEX FORMATION | Emory University (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009021114-A1 | PREPARATION OF SYNTHETIC NUCLEOSIDES VIA π-ALLYL TRANSITION METAL COMPLEX FORMATION | EMORY UNIVERSITY (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204463-A1 | Preparation Of Synthetic Nucleosides via Pi-Allyl Transition Metal Complex Formation | PAICS, POLRMT, ZC3HAV1 | SLC22A1 2279/4885POLA1 22/4885XDH 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.